"Roche has committed to transparent pricing and patent policies to address barriers to its HIV diagnostics tests and second-line HIV protease inhibitor medicine in low- and middle-income countries.
Roche supplies its protease inhibitor Invirase (saquinavir) at non-profit prices for people living in these countries, including all of sub Saharan Africa (SSA). This covers 63 countries, which are home to 64% of all people living with HIV/AIDS.
These are the lowest prices at which the medicines can viably be sold in the long term and do not reflect research or development costs, marketing costs, distribution costs or company overheads. Roche also supplies Invirase at significantly reduced prices in middle-income and emerging countries where HIV/AIDS is a growing problem.
Since 2007, the company has provided Valcyte (valganciclovir), an oral medication for treating AIDS-related cytomegalovirus retinitis (CMVR), at reduced prices for AIDS treatment programmes led by non-governmental organisations in low- and middle-income countries and in sub-Saharan Africa. In 2013, through a purchase agreement with the Medicines Patent Pool, Roche further reduced the price for Valcyte for use in HIV patients, making it 90% cheaper for 138 developing countries, including a number of upper middle-income countries such as India and China.
Through the AmpliCare program, Roche supplies diagnostic HIV tests at the lowest possible price in SSA countries and several countries in South America and Asia.
Roche does not file for new patents or enforce existing patents on Roche medicines in Least Developed Countries (LDCs) or low income countries. In addition, Roche does not file or enforce patents for antiretroviral HIV medicines in sub-Saharan Africa. Not applying patents in these regions enables generic versions of Roche medicines to be produced and distributed in these countries. In addition, through programs like Roche’s Technology Transfer Initiative (completed in 2010), local manufacturers now have the necessary skills to produce generic versions of the HIV medications."
|Location||East Asia and Pacific, West Africa, Central Africa, Central Asia, Eastern Africa, Latin America and Caribbean, South Asia, Southern Africa|